Q29. Increased dietary folic acid intake by women in childbearing age has led to ______ % reduction in the occurrence of neural tube defects. A. 10-30% B. 30-50% C. 50-70% D. 70-90% Test your knowledge by reviewing past quiz questions here: buff.ly/8mRhfns

Join a global community shaping the future of clinical cancer genomics. As a CGC member, you’ll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide.

The Cancer Genomics Consortium (CGC) is looking for dedicated CGC members to join our newest Working Group: Clinical Implementation of Multimodal Liquid Biopsy Cancer Testing. Click here to apply: buff.ly/AVhpqKO #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics

🧬 Join the Cancer Genomics Community! Expand your network and impact. Enroll today! buff.ly/ZkvNlaW #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular #CancerGenomics #Membership

Q29. Increased dietary folic acid intake by women in childbearing age has led to ______ % reduction in the occurrence of neural tube defects. A. 10-30% B. 30-50% C. 50-70% D. 70-90% Type your answer in the chat below and come back next week for the answer and explanation!

Q28. What is NOT a possible explanation for a deletion of one signal (green or orange) of a break apart probe? A. Typical result B. Regional deletion C. Deletion causing fusion D. Unbalanced rearrangement

Join us in congratulating Katie Schieffer, PhD, FACMG who is being featured in our December #CGCspotlight! Katie is a member of the Genomic Resources Development Committee and the Genomic Diagnosis of Sarcoma Working Group. Learn more here: buff.ly/5sGAxRY

We invite you to attend the monthly Collaborative Genomics Case Conference Webinar. This month's case conference webinar will include two case presentations. You can find more information here: buff.ly/w0NzXJ6 #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics

Join a global community shaping the future of clinical cancer genomics. As a CGC member, you’ll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. Learn more: buff.ly/tS7YP02

Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular

Q28. What is NOT a possible explanation for a deletion of one signal (green or orange) of a break apart probe? A. Typical result B. Regional deletion C. Deletion causing fusion D. Unbalanced rearrangement Type your answer in the chat below and come back next week for the answer and explanation!

There has never been a more exciting time to be a professional working in the field of Cancer Genomics! CGC members have the opportunity to help shape the field as we engage in projects to improve research, resources, and clinical practice in Cancer Genomics. Learn more here: buff.ly/tS7YP02

Thank you for your consideration in making a tax-deductible contribution to help us continue advancing high-quality genomic interpretation and improving patient care. Click here to donate: buff.ly/Jzr5229

The CGC Communications Committee is chiefly responsible for the CGC website, member management system, and social media profiles, promoting awareness and visibility of the CGC. Learn more about the communications committee here: buff.ly/eW1mD4R

On Giving Tuesday, we hope you’ll consider making a tax-deductible contribution to help us continue advancing high-quality genomic interpretation and improving patient care. Click here to donate today: buff.ly/HKj8izN

Next week, the Cancer Genomics Consortium (CGC) will participate in Giving Tuesday, a global day of generosity, for the first time and we invite you to join us in supporting the future of cancer genomics. Learn how you can support the CGC here: buff.ly/Jzr5229

Join a global community shaping the future of clinical cancer genomics. As a CGC member, you’ll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. buff.ly/tS7YP02

Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel? A. MEN1 B. MEN2 C. MSH3 D. RET

Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular

Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel? A. MEN1 B. MEN2 C. MSH3 D. RET

Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?: A. 1p32 gain B. t(4;14) C. t(11;14) D. Trisomy 8

Join us in congratulating Ninette Cohen, PhD, FACMG who is being featured in our November #CGCspotlight! Ninette is a member of the Communications Committee where she serves as chair of the website subcommittee. Learn more here: buff.ly/5sGAxRY #CGCVolunteers #genomics #cancer #research #genetics

Registration Now Open: The Cancer Genomics Consortium (CGC) invites you to attend Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/9E1KZio #CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics

Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?: A. 1p32 gain B. t(4;14) C. t(11;14) D. Trisomy 8 Type your answer in the chat below and come back next week for the answer and explanation!

Mark your calendar with #CGCAnnual2026—we look forward to seeing you in Houston next year! #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular

The Education Committee is comprised of dedicated members who are committed to providing varied and interesting educational resources to our members throughout the year. We always welcome suggestions and feedback from members. Learn more about the committees here: buff.ly/q0FY6mo #CGCVolunteers

Final Day! Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics

Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4? A. Gain of chromosome 10 B. TERT promoter mutation C. EGFR gene amplification D. B and C

A quick reminder to join us tomorrow for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing." Click here to learn more and register today: buff.ly/Oxz6OQh

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics

Join us next week for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing" on October 28, 2025. Click here to learn more and register today: buff.ly/Oxz6OQh

Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4? A. Gain of chromosome 10 B. TERT promoter mutation C. EGFR gene amplification D. B and C

The Cancer Genomics Consortium (CGC) and Oxford Nanopore Technologies invite you to attend Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing on October 28, 2025. Click here to learn more and to register today: buff.ly/Oxz6OQh

Join us in congratulating Teresa A. Smolarek, PhD, FACMG who is being featured in our October #CGCspotlight! Teresa is a member of the Genomic Diagnosis of Sarcoma Working Group and the Education Committee. Learn more here: buff.ly/UkJ5OXS #CGCVolunteers #genomics #cancer #research #genetics

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics

Don't miss out! The new letter from the CGC President is here, sharing the latest vision and updates for the future of the Cancer Genomics Consortium. Read the full message now: buff.ly/iuQLfTt #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics

Q24. Prader-Willi syndrome result from ______ in a majority of cases. A. Imprinting defect B. UPD15 C. Deletion D. Path seq variant in UBE3A

Please join us on Tuesday, October 14, for the monthly Collaborative Genomics Case Conference Webinar. This event is a partnership between the University of Wisconsin-Madison ICEP and the Cancer Genomics Consortium. Learn more here: buff.ly/bKZ6sKX #genomics #cancer #research #genetics

CGC is dedicated to supporting the Early Career community with low trainee membership fees, outstanding early career programing, and incredible networking opportunities! CGC is the place to join for Early Career individuals in the Genetics and Genomics field.

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. #CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics

Reminder: The CGC Early Career Committee will host a webinar on October 8, 2025 focused on digital networking for early career professionals. Click here to register now: buff.ly/9FUUBF8 #CGCAnnual2025 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular

Q24. Prader-Willi syndrome result from ______ in a majority of cases. A. Imprinting defect B. UPD15 C. Deletion D. Pathogenic sequence variant in UBE3A Type your answer in the chat below and come back next week for the answer and explanation!

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. Click here to learn more: buff.ly/9LJ5mTV #CGCAnnual2026 #genomics #cancer #research #genetics

The CGC Early Career Committee will host a webinar on October 8, 2025 focused on digital networking for early career professionals. Click here to register now: buff.ly/9FUUBF8 #CGCAnnual2025 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. Click here to learn more: buff.ly/zya2jw8 #CGCAnnual2026 #genomics #cancer #research #genetics

Q23. A 4 year old girl came for genetic testing for malignant neoplasm of peripheral nerves (two tumors next to spine and adrenal gland) and constipation. Which gene will be likely found to be altered?: A.CDH1 B.PHOX2B C.NF1 D. POLE

Q23. A 4 year old girl came for genetic testing for malignant neoplasm of peripheral nerves (two tumors next to spine and adrenal gland) and constipation. Which gene will be likely found to be altered?: A. CDH1 B. PHOX2B C. NF1 D. POLE

Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX. Click here to learn more: buff.ly/zya2jw8 #CGCAnnual2026 #genomics #cancer #research #genetics

Q22. The Pedigree in the image shows which type of inheritance pattern: A. Autosomal dominant B. X-linked dominant C. X-linked recessive D. Mitochondrial

Q22. The Pedigree in the image shows which type of inheritance pattern: A. Autosomal dominant B. X-linked dominant C. X-linked recessive D. Mitochondrial Type your answer in the chat below and come back next week for the answer and explanation!